SLC7A11 and hepatocellular carcinoma: Characteristically, the antitumor-drug nanocarrier graphdiyne oxide (GDYO) has been suggested to promote endothelial HCC cell proliferation via receptor-mediated lysis and to be involved in the release of sorafenib, providing chemotherapeutic effects, and SLC7A11, inducing cancer cells to enter the iron cycle [229,230].